Cambridge Healthtech Institute’s Inaugural

Precision Medicine Beyond Oncology

Diagnostics and Personalized Medicine in Immunology, Neurology, and Metabolic Diseases

March 12-13, 2025

While most precision medicine success stories have been in oncology, similar strategies are being applied in other therapeutic areas, including immunology, neurology, metabolic, and cardiovascular diseases. Driven by novel blood-based diagnostics, genetic testing, and emerging biomarkers, precision medicine promises to identify patient populations, accelerate clinical trials, and improve market access across therapeutic indications. Cambridge Healthtech Institute’s Inaugural Precision Medicine Beyond Oncology meeting will address emerging neuro-diagnostics, patient stratification strategies for immune-mediated diseases, predicting responders to GLP-1 receptor agonists, and more.

Coverage will include, but is not limited to:

Predicting response to GLP-1 receptor agonists
Neuro-diagnostics to identify early-stage neurodegenerative patients
Understanding genetic predisposition to autoimmune conditions
Developing fit-for-purpose precision medicine strategies
Identifying and targeting addressable patient segments
New technologies to diagnose disease and determine risk
Wearable technologies to monitor health metrics
Equitable access to precision medicine advances

The deadline for priority consideration is September 13, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: